GRENOBLE, France--(BUSINESS WIRE)--
CEA-Leti announced today 1 million in funding from bpifrance to accelerate preclinical development of a liver-cancer detection system called LipImage 815.
The grant, awarded through bpifrance s Strategic Industrial Innovation (ISI) program, will accelerate the development of LipImage 815, including production and regulatory toxicity evaluation. It also supports the launch of NICE (Nano Innovation for Cancer), the first consortium of nanomedicine stakeholders in France focused on aspects of characterization and industrialization. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France (www.medicen.org).
Developed by Leti, LipImage 815 is a fluorescent imaging agent based on Letis Lipidots platform that uses lipid nanoparticles to carry a fluorescent substance to targeted cells and improve the effectiveness of diagnosis. It will be used to test for early stages of liver cancer.
Consisting of five public and private partners and led by BioAlliance Pharma, the NICE consortium includes partners with deep expertise in the field of nanomedicine. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner.
In addition to Leti, the consortium includes:
By bringing together a highly experienced team of specialists in various fields of nanomedicine, this program can significantly accelerate the development of an effective new tool for diagnosing liver cancer, said Laurent Malier, Leti CEO. It also leverages Letis achievements in the Lipidots platform, and provides another avenue for us to bring our innovations to market.
Aboutbpifrance s Strategic Industrial Innovation (ISI) program
The Strategic Industrial Innovation program promotes the emergence of European champions. It supports ambitious, innovative collaborative projects through to industrialization, driven by innovative medium-sized companies (less than 5000 employees) and small businesses (less than 250 employees). These highly promising projects are aimed at the commercialization of products which result from technological breakthroughs and which not be possible without fostering measures from the public sector. Funding is generally in the 3-10 million range, as grants-in aid and loans which are repayable if the project is a success.
About CEA-Leti
See the original post here:
CEA-Leti Announces €1 Million from bpifrance (ex OSEO) to Speed Preclinical Development of Cancer-Detecting ...